Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs

Health Economics Review

Volumn 2, Issue 1, 2012, Pages 1-9

  Homar, Francesc ^a   Lozano, Virginia ^b   Martínez Gómez, Juan ^a   Oyagüez, Itziar ^b   Pareja, Antonio ^a   Payeras, Antoni ^a   Serrano, Joaquín ^a   Carratalá, Carmen ^a   Casado, Miguel Ángel ^b  

^a HOSPITAL SON LLÀTZER   (Spain)

^b Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

Author keywords

Antiretrovirals; Cost analysis; Fixed dose combination; HIV; Spain

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR; GENERIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTEGRASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ABNORMAL DREAMING; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CONCENTRATION LOSS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VOMITING;

EID: 84971254207     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/2191-1991-2-16     Document Type: Article

References (16)

1. Epidemiology HIV-1 /AIDS. http://www. unaids. org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2225_UNAIDS_datatables_en. pdf.
2. Flexner C: HIV drug development: the next 25 years. Nat Rev Drug Discov 2007, 6(12): 959-966.
3. Llibre JM, Falco V, Tural C, Negredo E, Pineda JA, Muñoz J, Ortega E, Videla S, Sirera G, Martinez E, Miralles C, Iribarren J, Galindo MJ, Domingo P, D'Arminio-Monforte A, Miro JM, Clotet B: The changing face of HIV/AIDS in treated patients. Curr HIV Res 2009, 7(4): 365-377.
4. Spanish general council of official colleges of pharmacists - botplus. https://botplusweb. portalfarma. com/.
5. Royal decree-law 4/2010, May 26. http://www. msps. es/profesionales/farmacia/pdf/margenesFactoresConversion. pdf.
6. Spanish database of healthcare costs - Oblikue (eSalud). http://www. oblikue. com/bddcostes/.
7. Esté JA, Cihlar T: Current status and challenges of antiretroviral research and therapy. Antiviral Res 2010, 85(1): 25-33.
8. Llibre JM, Schapiro JM, Clotet B: Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure. Clin Infect Dis 2010, 50(6): 872-881.
9. McColl DJ, Margot N, Chen SS, Harris J, Borroto-Esoda K, Miller MD: Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz. HIV Clin Trials 2011, 12(2): 61-70.
10. Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, Schols D, van Laethem K, Alcaro S, Costa G, Tommasi C, Zaccarelli M, Narciso P, Antinori A, Ceccherini-Silberstein F, Balzarini J, Perno CF: Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. J Acquir Immune Defic Syndr 2010, 55(3): 336-344.
11. Maserati R, De Silvestri A, Uglietti A, Colao G, Di Biagio A, Bruzzone B, Di Pietro M, Re MC, Tinelli C, Zazzi M, ARCA Collaborative Group: Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. AIDS 2010, 24(7): 1013-1018.
12. Sax PE, Meyers JL, Mugavero M, Davis KL: Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One 2012, 7(2): e31591.
13. Cohen C, Davis KL, Meyers JL: Association between daily antiretroviral pill burden and hospitalization risk in a medicaid population With HIV. Chicago, IL; 2011.[CAAC'2011: 51st interscience conference on antimicrobial agents and chemotherapy].
14. Lubomirov R, Colombo S, di Iulio J, Ledergerber B, Martinez R, Cavassini M, Hirschel B, Bernasconi E, Elzi L, Vernazza P, Furrer H, Günthard HF, Telenti A, Swiss HIV Cohort Study: Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis 2011, 203: 246-257.
15. Pollock K, Stebbing J, Bower M, Gazzard B, Nelson M: Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity. J Antimicrob Chemother 2006, 58(1): 227-228.
16. Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A: Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009, 51(2): 163-174.